ReviewFrontiers in cardiovascular medicine2026
Exosome-delivered bioactive molecules regulate macrophage polarization in atherosclerosis and myocardial infarction: mechanisms and therapeutic potential.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes, by carrying biologically active molecules, constitute the core network of inter-cell communication and play an important role in the regulation of macrophage polarization. The dynamic balance of macrophage polarization is a key determinant of atherosclerosis plaque stability and cardiac repair after myocardial infarction. This review systematically summarizes the molecular mechanisms by which exosomes and their specific molecules accurately regulate M1/M2 polarization of macrophages. We also focused on the mechanism of action by which exosomes play a dual role in promoting or inhibiting the physiological and pathological environment of AS and MI. In addition, the clinical transformation potential and current challenges of new biomarkers and treatment strategies (such as engineered exosomes, drug carriers) are also discussed, which is expected to bring new treatment strategies to the treatment of cardiovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.